REZOLUTE, INC. Net Change in Cash
REZOLUTE, INC. (RZLT) reported Net Change in Cash of -$83.49 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-24.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-09-24
- REZOLUTE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-09-30 was -$85.01M.
- REZOLUTE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-09-30 was -$59.92M.
- REZOLUTE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-09-30 was -$7.98M, a 303.96% decline year-over-year.
- REZOLUTE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2022-09-30 was $3.91M.
- REZOLUTE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2026 was -$83.49M, a 452.12% decline from fiscal 2025.
- REZOLUTE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $23.71M, a 56.38% decline from fiscal 2024.
- REZOLUTE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $54.36M.
- REZOLUTE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$134.37M, a 222.87% decline from fiscal 2022.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$83.49M 10-K · filed 2026-09-24 | |||
| 2026-03-31 | -$82.87M 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | -$82.16M 10-Q · filed 2026-02-12 | |||
| 2025-09-30 | -$85.01M 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $23.71M 10-K · filed 2026-09-24 | |||
| 2025-03-31 | -$55.80M 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | -$61.46M 10-Q · filed 2026-02-12 | |||
| 2024-09-30 | -$59.92M 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | $54.36M 10-K · filed 2025-09-17 | |||
| 2024-03-31 | -$10.11M 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | -$3.53M 10-Q · filed 2025-02-12 | |||
| 2023-09-30 | -$7.98M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | -$134.37M 10-K · filed 2024-09-19 | |||
| 2023-03-31 | -$116.67M 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | -$3.66M 10-Q · filed 2024-02-13 | |||
| 2022-09-30 | $3.91M 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | $109.36M 10-K · filed 2023-09-14 | |||
| 2022-03-31 | $27.37M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $41.36M 10-Q · filed 2023-02-10 | |||
| 2021-09-30 | -$3.75M 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | $31.09M 10-K · filed 2022-09-15 | |||
| 2021-03-31 | $22.03M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $27.64M 10-Q · filed 2022-02-09 | |||
| 2020-09-30 | -$3.55M 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | -$1.62M 10-K · filed 2021-09-15 | |||
| 2020-03-31 | $2.46M 10-Q · filed 2021-05-17 | |||
| 2019-12-31 | $8.14M 10-Q · filed 2021-02-10 | |||
| 2019-09-30 | $13.64M 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | $9.93M 10-K · filed 2020-10-13 | |||
| 2019-03-31 | $13.70M 10-Q · filed 2020-05-14 | |||
| 2018-12-31 | -$1.39M 10-Q · filed 2020-02-12 | |||
| 2018-09-30 | -$1.25M 10-Q · filed 2019-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |